Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9

Bone Marrow Transplantation volume 44, pages 295–302 (2009)Cite this article

Abstract

Toll-like receptor 9 (TLR9) is part of the innate immune system, which is activated by CpG oligonucleotides (ODNs) and produces potent Th1-type innate and adaptive immune responses. It is reported that TLR9 gene variants, T1486C and T1237C, are associated with a reduced TLR9 expression compared with the wild-type gene. In two cohort analyses, we evaluated the influence of these gene variants on the outcome of transplant in 413 patients and donors. A retrospective analysis of the first cohort (n=293) showed that the homozygous CC gene variant of TLR9 (1486) compared with TC/TT gene variants was significantly associated with a markedly improved 5-year TRM (11.7 versus 36.4%, P<0.003), 5-year OS (86.1 vs 48.3%, P<0.001) and a lower relapse rate (13.2 vs 33.3%, P<0.007), whereas the occurrence of acute GVHD was not different. A prospectively performed analysis of the second cohort (n=120) and multivariate analyses confirmed the influence of the CC gene variant on these end points. Compared with patients with TC/TT gene at position 1486 of TLR9, patients with the homozygous CC gene variant had a lower TLR9 mRNA expression and a delayed T-cell immune reconstitution after transplant, which might prevent them from overwhelming immune responses as sepsis or systemic inflammatory response syndrome (SIRS) associated with an increased TRM. In vitro studies using CpG-rich ODNs showed an upregulation of TLR9 expression in cell lines with CC gene variant, but not in cell lines with wild-type gene.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135–145 (review).

    Article  CAS  PubMed  Google Scholar 

  2. Medzhitov R, Janeway Jr C . The Toll receptor family and microbial recognition. Trends Microbiol 2000; 8: 452–456.

    Article  CAS  PubMed  Google Scholar 

  3. Chiffoleau E, Heslan J-M, Heslan M, Louvet C, Condamine T, Cuturi M-C . TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol 2007; 19: 193–201.

    Article  CAS  PubMed  Google Scholar 

  4. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S et al. Lymphoma Immunotherapy with CpG oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself. J Immunol 2007; 179: 2493–2500.

    Article  CAS  PubMed  Google Scholar 

  5. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL et al Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J. Immunol 2005; 174: 5193–5200.

    Article  CAS  PubMed  Google Scholar 

  6. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DCG et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007; 8: 772–779.

    Article  CAS  PubMed  Google Scholar 

  7. Ashman RF, Goeken, JA, Drahos J, Lenert P . Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005; 17: 411–420.

    Article  CAS  PubMed  Google Scholar 

  8. Krieg AM . Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161–167.

    Article  CAS  PubMed  Google Scholar 

  9. Lin M-T, Storer B, Martin PJ, Tseng L-H, Gooley T, Chen P-J et al. Relation of an interleukin-10 promotor polymorphism to graft-versus-host disease and survival after hematopoietic cell transplantation. N Engl J Med 2003; 349: 2201–2210.

    Article  CAS  PubMed  Google Scholar 

  10. Elmaagacli AH, Koldehoff M, Hindahl H, Trenschel R, Peceny R, Ottinger H et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute GVHD in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247–254.

    Article  CAS  PubMed  Google Scholar 

  11. Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW . Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007; 40: 659–664.

    Article  CAS  PubMed  Google Scholar 

  12. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW . Relation of an Interleukin-23 Receptor gene polymorphism to Graft-versus-Host Disease after Hematopoietic-Cell Transplantation. Bone Marrow Transplant 2008; 41: 821–826.

    Article  CAS  PubMed  Google Scholar 

  13. Tao K, Fujii M, Tsukumo S-I, Maekawa Y, Kishihara K, Kimoto Y et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007; 66: 905–909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Berghöfer B, Frommer T, König IR, Ziegler A, Chakrabortyz T, Bein G et al. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance. Clin Exp Allergy 2005; 35: 1147–1154.

    Article  PubMed  Google Scholar 

  15. Novak N, Yu C-F, Bussmann C, Maintz L, Peng W-M, Hart J et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007; 62: 766–772.

    Article  CAS  PubMed  Google Scholar 

  16. Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched unrelated donors. Blood 2003; 102: 1131.

    Article  CAS  PubMed  Google Scholar 

  17. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared to bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.

    CAS  PubMed  Google Scholar 

  18. Maniatis T, Fritsch EF, Sambrook J . Molecular Cloning . A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1982.

    Google Scholar 

  19. Hamann L, Hamprecht A, Gomma A, Schumann RR . Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor-2, -4, -9 genes. J Immunol Methods 2004; 285: 281–291.

    Article  CAS  PubMed  Google Scholar 

  20. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer UW et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of bcr-abl fusion transcripts detected using a new real-time polymerase chain reaction method. B J Haemtol 2001; 113: 1072–1075.

    Article  CAS  Google Scholar 

  21. Steckel N, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH . Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis with myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518–1520.

    Article  CAS  PubMed  Google Scholar 

  22. Satoh, Akatsu T, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M . Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. Am Heart J 2007; 154: 581–588.

    Article  CAS  PubMed  Google Scholar 

  23. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H . Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.

    CAS  PubMed  Google Scholar 

  24. Prezpiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    Google Scholar 

  25. Sullivan KM, Agura E, Anasetti C, Appelbaum D, Badger C, Barman S et al. Chronic graft-versus-host-disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  26. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  27. Cox DR . Regression models and life-tables. J R Stat Soc 1972; 34: 187.

    Google Scholar 

  28. Calcaterra C, Sfondrini L, Rossigni A, Sommaria M, Rumio C, Me'nard S, Balsari A . Critical Role of TLR9 in Acute Graft-versus-Host Disease. J of Immunol 2008; 181: 6132–6139.

    Article  CAS  Google Scholar 

  29. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672–1678.

    CAS  PubMed  Google Scholar 

  30. Blazar BR, Krieg AM, Taylor PA . Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001; 98: 1217–1225.

    Article  CAS  PubMed  Google Scholar 

  31. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF . TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007; 37: 2205–2213.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Silke Gottwald and Christiane Schary (both form Essen, Germany) for their excellent technical assistance with genotyping analyses. This study was supported by grants from the Deutsche Krebshilfe, Deutsche Josè Carreras-Leukämie-Stiftung and Kulturstiftung Essen. Contributions: The first author designed and performed the research and also wrote the paper. Michael Koldehoff collected the data, performed the research and approved the paper. Dierich W Beelen collected patient data and approved the paper.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany

    A H Elmaagacli, M Koldehoff & D W Beelen

Authors
  1. A H Elmaagacli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Koldehoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D W Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A H Elmaagacli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elmaagacli, A., Koldehoff, M. & Beelen, D. Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. Bone Marrow Transplant 44, 295–302 (2009). https://doi.org/10.1038/bmt.2009.32

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.32

Keywords

This article is cited by

Search

Advanced search

Quick links